Jaguar Health, Inc. (JAGX)

NASDAQ: JAGX · Real-Time Price · USD
4.620
+0.100 (2.21%)
At close: May 29, 2025, 4:00 PM
4.620
0.00 (0.00%)
Pre-market: May 30, 2025, 4:49 AM EDT
2.21%
Market Cap 5.84M
Revenue (ttm) 11.55M
Net Income (ttm) -39.73M
Shares Out 1.26M
EPS (ttm) -93.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 95,110
Open 4.550
Previous Close 4.520
Day's Range 4.440 - 4.900
52-Week Range 4.020 - 130.250
Beta 0.96
Analysts Strong Buy
Price Target 60.00 (+1,198.7%)
Earnings Date May 15, 2025

About JAGX

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiret... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 49
Stock Exchange NASDAQ
Ticker Symbol JAGX
Full Company Profile

Financial Performance

In 2024, Jaguar Health's revenue was $11.69 million, an increase of 19.75% compared to the previous year's $9.76 million. Losses were -$38.49 million, -6.80% less than in 2023.

Financial Statements

Analyst Forecast

According to one analyst, the rating for JAGX stock is "Strong Buy" and the 12-month stock price forecast is $60.0.

Price Target
$60.0
(1,198.70% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and ...

8 days ago - Accesswire

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

As announced , initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient...

9 days ago - Accesswire

Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript

Jaguar Health, Inc. (NASDAQ:JAGX) Q1 2025 Earnings Conference Call May 15, 2025 4:15 PM ET Company Participants Lisa Conte – Founder, President, and Chief Executive Officer Carol Lizak – Chief Financ...

14 days ago - Seeking Alpha

Jaguar Health Reports First Quarter 2025 Financials

The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4 ...

14 days ago - Accesswire

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

Click here to register Company plans to file its Earnings Report on May 15, 2025 on Form 10-Q for the quarter ended March 31, 2025 SAN FRANCISCO, CA / ACCESS Newswire / May 14, 2025 / Jaguar Health, I...

15 days ago - Accesswire

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Company's Canalevia®-CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only tre...

21 days ago - Accesswire

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical Guidance Click here to access replay of company's April 30, 2025 investor webcast SAN FRA...

22 days ago - Accesswire

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI C...

4 weeks ago - Accesswire

REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for c...

4 weeks ago - Accesswire

Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for c...

4 weeks ago - Accesswire

Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and mi...

6 weeks ago - Accesswire

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 20...

6 weeks ago - Accesswire

Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most signifi...

7 weeks ago - Accesswire

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 res...

7 weeks ago - Accesswire

Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement...

2 months ago - Accesswire

Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript

Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Conference Call Participants Operator Greetings, and welcome to the Jaguar Health Inv...

2 months ago - Seeking Alpha

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus ...

2 months ago - Accesswire

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA In dogs undergoing chemotherapy, as is the case with pe...

2 months ago - Accesswire

Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study

The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poste...

2 months ago - Accesswire

Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts

Click here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference Click here to register for Jaguar's March 31 investor webcast Company plans to file its annual repor...

2 months ago - Accesswire

Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules

SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, th...

2 months ago - Accesswire

Jaguar Health, Inc. Announces Reverse Stock Split

Reverse split approved at March 2025 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025 SAN FRANCISCO, CA / ACCESS Newswire...

2 months ago - Accesswire

Jaguar Health Reports Approval of All Proposals at March 2025 Special Meeting of Stockholders

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis...

2 months ago - Accesswire

Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis...

3 months ago - Accesswire

Jaguar Receives Regulatory Clearance in Germany and Italy for Crofelemer for Rare Disease Study - Short Bowel Syndrome with Intestinal Failure (SBS-IF)

This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indicat...

3 months ago - Accesswire